APA (7th ed.) Citation

Wilcock, D., Jedrzkiewicz, J., Cleary, A. S., Beech, C., & Gulbahce, H. E. (2026). Breast Cancers With Discordant Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization-Positive (Group 1) and Immunohistochemistry-Negative (0/11) Results Following American Society of Clinical Oncology/College of American Pathologists Guideline. Archives of Pathology & Laboratory Medicine, 150(7), 503. https://doi.org/10.5858/arpa.2025-0490-OA

Chicago Style (17th ed.) Citation

Wilcock, Diane, Jolanta Jedrzkiewicz, Allison S. Cleary, Cameron Beech, and H. Evin Gulbahce. "Breast Cancers With Discordant Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization-Positive (Group 1) and Immunohistochemistry-Negative (0/11) Results Following American Society of Clinical Oncology/College of American Pathologists Guideline." Archives of Pathology & Laboratory Medicine 150, no. 7 (2026): 503. https://doi.org/10.5858/arpa.2025-0490-OA.

MLA (9th ed.) Citation

Wilcock, Diane, et al. "Breast Cancers With Discordant Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization-Positive (Group 1) and Immunohistochemistry-Negative (0/11) Results Following American Society of Clinical Oncology/College of American Pathologists Guideline." Archives of Pathology & Laboratory Medicine, vol. 150, no. 7, 2026, p. 503, https://doi.org/10.5858/arpa.2025-0490-OA.